Trial of d-alpha-tocopherol in Huntington's disease
| Autor: | Susan E. Folstein, Fred Bylsma, S. E. Starkstein, Paul R. McHugh, Jason Brandt, Joseph T. Coyle, Gary A. Chase, Carol Efron Peyser, Marshal F. Folstein, Joseph R. Cockrell |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
medicine.medical_specialty
Pathology Disease Neuropathology Placebo Gastroenterology Antioxidants Central nervous system disease Placebos Degenerative disease Huntington's disease Double-Blind Method Isomerism Internal medicine medicine Humans Vitamin E Prospective Studies Prospective cohort study business.industry Therapeutic effect medicine.disease Psychiatry and Mental health Oxidative Stress Huntington Disease Treatment Outcome Chromosomes Human Pair 4 business |
| Zdroj: | The American journal of psychiatry. 152(12) |
| ISSN: | 0002-953X |
| Popis: | Objective Evidence suggests that the neuropathology of Huntington's disease, a neuropsychiatric disorder due to a mutation on chromosome 4, results from excessive activation of glutamate-gated ion channels, which kills neurons by oxidative stress. Therefore, the authors hypothesized that alpha-tocopherol, which reduces oxyradical damage to cell membranes, might slow the course of Huntington's disease. Method A prospective, double-blind; placebo-controlled study of high-dose d-alpha-tocopherol treatment was carried out with a cohort of 73 patients with Huntington's disease who were randomly assigned to either d-alpha-tocopherol or placebo. Patients were monitored for changes in neurologic and neuropsychologic symptoms. Results Treatment with d-alpha-tocopherol had no effect on neurologic and neuropsychiatric symptoms in the treatment group overall. However, post hoc analysis revealed a significant selective therapeutic effect on neurologic symptoms for patients early in the course of the disorder. Conclusions Antioxidant therapy may slow the rate of motor decline early in the course of Huntington's disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|